BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SYN115: Phase IIb started

Biotie began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate 60, 120, 180 and 240 mg oral SYN115 twice daily in 400 patients treated with levodopa. Biotie gained SYN115 through...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >